Female Sexual Dysfunction (FSD): female sexual arousal disorder (SFSAD), genital, female sexual arousal disorder (GFSAD), female hypoactive sexual desire disorder are disorders that, in a survey conducted by the American Medical Association in 1999, affects approximately 43% of women in the United States.

Age may not be a significant factor. However, there is evidence that the majority of female sexual dysfunction happens after menopause, when hormone production drops and vascular conditions are more common.

There are no FDA-approved drug treatments for FSD.

Bremelanotide (P-141), a synthetic analog of a-melanocyte stimulating hormone, and an active metabolite of Melanotan-II (MTII), have been in clinical development for the treatment of FSD.

Bremelanotide was effective and well tolerated in menstruating women with FSAD but was discontinued due to side effects (increase in blood pressure).